|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EMBRYONIC STEM CELLS: CHARACTERIZATION SERIES |
Departments of aPhilosophy and
bBiology, Wesleyan University, Middletown, Connecticut, USA
Key Words. Human embryonic stem cell therapy • Ethics • Oversight
Correspondence: Laura Grabel, Ph.D., Department of Biology, Wesleyan University, Middletown, Connecticut 06459-0170, USA. Telephone: 860-685-3238; Fax: 860-685-3279; e-mail: lgrabel{at}wesleyan.edu
Received February 21, 2006;
accepted for publication June 15, 2006.
First published online in STEM CELLS EXPRESS June 22, 2006.
Despite the identified therapeutic potential of embryonic stem cells for treating human disease and injury, a number of roadblocks, scientific and ethical, stand in the way of progress toward this goal. We identify six areas of particular interest: tumorigenicity, animal product contamination, genetic compatibility, funding, cell type for transplantation, "embryo-friendly" derivation methods and discuss avenues for moving beyond the difficulties.
This article has been cited by other articles:
![]() |
P. A. Schweizer, U. Krause, R. Becker, A. Seckinger, A. Bauer, C. Hardt, V. Eckstein, A. D. Ho, M. Koenen, H. A. Katus, et al. Atrial-Radiofrequency Catheter Ablation Mediated Targeting of Mesenchymal Stromal Cells Stem Cells, June 1, 2007; 25(6): 1546 - 1551. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
